PROMIS NEUROSCIENCES INC. Interest Receivable
PROMIS NEUROSCIENCES INC. (PMN) had Interest Receivable of $215.23 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2026-08-13
- 2026-06-30: Interest Receivable $215.23K.
- 2026-03-31: Interest Receivable $238.33K.
- 2025-12-31: Interest Receivable $36.52K.
- 2025-09-30: Interest Receivable $86.06K.
| Period end | Interest Receivable | Interest Receivable as first filed |
|---|---|---|
| 2026-06-30 | $215.23K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $238.33K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $36.52K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $86.06K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $29.48K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $54.56K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $78.03K 10-K · filed 2026-03-25 | |
| 2024-09-30 | $130.28K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $72.25K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $76.81K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $78.64K 10-K · filed 2025-03-31 | $58.15K 10-K · filed 2024-04-01 |
| 2023-09-30 | $82.06K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |